

SARAH CANNON | ASCO® 2019

ABSTRACT PRESENTATION CALENDAR

THURSDAY, MAY 30th
1:45pm - 3:30pm
Sessions

Time Begin	Time End	ASCO ID (Poster Board #)	Location	Presentation Title	Presenter	Sarah Cannon Co-Authors	ASCO Selection Status	Session Category
1:45pm	3:05pm		S100A	From Rarity to Common Expectation: Tripling Clinical Trial Recruitment [PRE-SEMINAR; PAID SESSION]	TM Bauer		Oral	New Drugs in Oncology Seminar

FRIDAY, MAY 31st
1:00pm - 6:00pm
Sessions

Time Begin	Time End	ASCO ID (Poster Board #)	Location	Presentation Title	Presenter	Sarah Cannon Co-Authors	ASCO Selection Status	Session Category
1:24pm	1:36pm	9010	Hall D1	Safety and preliminary antitumor activity of U3-1402: A HER3-targeted antibody drug conjugate in EGFR TKI-resistant, EGFRm NSCLC	PA Janne	ML Johnson	Oral Abstract Session	EGFR and ROS1: Targeting Resistance (1:00 - 2:30pm)
4:30pm	5:30pm		Hall D1	Case 3: Managing Immunotherapy in Patients with Renal Insufficiency (PD-L1 Low)	ML Johnson		Education Session	Challenges in Use of Immunotherapy in Non-Small Cell Lung Cancer: Where the Rubber Meets the Road
4:30pm	5:45pm		S404	The Metastatic Breast Cancer Project: Engaging Patients, Advancing Research	EP Hamilton		Education Session	Tweets, Chats, and Posts: Using Social Media to Transcend Boundaries and Create Opportunities for Patients
4:45pm	4:57pm	5006	Arie Crown Theater	First results from TITAN: A phase III double-blind, randomized study of apalutamide versus placebo in patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy	KN Chi	S Chowdhury	Oral	Genitourinary (Prostate) cancer (2:45 - 5:45pm)
5:10pm	5:30pm		E451	Barriers to CAR T-Cell Treatment in the Community	CR Bachier	CR Bachier	Oral	Education Session: The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity and Financial Burden

SARAH CANNON | ASCO® 2019

ABSTRACT PRESENTATION CALENDAR

SATURDAY, JUNE 1st

8:00 am - 1:00 pm

Posters

Time Begin	Time End	ASCO ID (Poster Board #)	Location	Presentation Title	Presenter	Sarah Cannon Co-Authors	ASCO Selection Status	Session Category
8:00am	11:00am	3049 (41)	Hall A	Genome-wide cell-free DNA (cfDNA) methylation signatures and effect on tissue of origin (TOO) performance	MC Liu	DR Spigel	Poster	Developmental Therapeutics and Tumor Biology (Nonimmuno)
8:00am	11:00am	3065 (57)	Hall A	Effectiveness of ASCO's adverse event reporting decision aid: results from an interventional study	KF Mileham	A Buchmeier	Poster	Developmental Therapeutics and Tumor Biology (Nonimmuno)
8:00am	11:00am	3085 (77)	Hall A	First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with relapsed/refractory (RR) malignant solid tumor and lymphoma: Preliminary data	JS Wang	JS Wang, J Karlix, KN Moore, TM Bauer, SV Ulahannan, MR Patel, EP Hamilton	Poster	Developmental Therapeutics and Tumor Biology (Nonimmuno)
8:00am	11:00am	3091 (83)	Hall A	A Phase 1b study of prexasertib, a checkpoint kinase (CHK1) inhibitor, and LY3023414, a dual inhibitor of class I phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) in patients with advanced solid tumors	DS Hong	KN Moore, JC Bendell, JS Wang, SV Ulahannan, ML Johnson, R Aljumaily, MR Patel	Poster	Developmental Therapeutics and Tumor Biology (Nonimmuno)
8:00am	11:00am	3094 (86)	Hall A	A first-in-human phase I/II trial of SRA737 (a Chk1 inhibitor) in subjects with advanced cancer	ER Plummer	H Arkenau	Poster	Developmental Therapeutics and Tumor Biology (Nonimmuno)
8:00am	11:00am	3095 (87)	Hall A	A phase I/II first-in-human trial of oral SRA737 (c Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer	U Banerji	H Arkenau	Poster	Developmental Therapeutics and Tumor Biology (Nonimmuno)
8:00am	11:00am	3098 (90)	Hall A	A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors	ML Johnson	ML Johnson, GS Falchook, SF Jones, D Strickland, C Greenlees, HA Burris, JS Wang	Poster	Developmental Therapeutics and Tumor Biology (Nonimmuno)
8:00am	11:00am	TPS3158 (144a)	Hall A	A phase I open label study evaluating VT1021 in patients with advanced solid tumors	M Cieslewicz	KN Moore, MR Patel	Poster	Developmental Therapeutics and Tumor Biology (Nonimmuno)
8:00am	11:00am	TPS3161 (145b)	Hall A	A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation	KP Papadopoulos	ML Johnson	Poster	Developmental Therapeutics and Tumor Biology (Nonimmuno)

SARAH CANNON | ASCO® 2019

ABSTRACT PRESENTATION CALENDAR

SATURDAY, JUNE 1st

8:00 am - 1:00 pm (Continued)

Posters

Time Begin	Time End	ASCO ID (Poster Board #)	Location	Presentation Title	Presenter	Sarah Cannon Co-Authors	ASCO Selection Status	Session Category
8:00am	11:00am	TPS3163 (146b)	Hall A	A phase I dose-escalation and immune biomarker study of intravenous FF-10832, liposomal gemcitabine, in patients with advanced solid tumors	EH Borazanci	GS Falchook, S Sen, SF Jones, EP Hamilton	Poster	Developmental Therapeutics and Tumor Biology (Nonimmuno)
8:00am	11:00am	TPS3166 (148b)	Hall A	A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (MDM2-p53 antagonist) in adult patients with advanced or metastatic solid tumors	CR Chong	TM Bauer, MR Patel	Poster	Developmental Therapeutics and Tumor Biology (Nonimmuno)
8:00am	11:00am	TPS3169 (149b)	Hall A	Phase 1, open-label, dose-escalation study of M3814 + avelumab 3 radiotherapy (RT) in patients (pts) with advanced solid tumors	JC Bendell	JC Bendell	Poster	Developmental Therapeutics and Tumor Biology (Nonimmuno)
8:00am	11:00am	2529 (173)	Hall A	Phase 1a/1b study of first-in-class B7-H4 antibody, FPA150, as monotherapy in patients with advanced solid tumors	JC Sachdev	TM Bauer	Poster	Developmental Immunotherapy and Tumor Immunobiology
8:00am	11:00am	2558 (202)	Hall A	Antitumor activity and safety of MK-1308 (anti-CTLA-4) plus pembrolizumab (pembro) in patients (pts) with non-small cell lung cancer (NSCLC): Updated interim results from a phase I study	R Perets	DR Spigel	Poster	Developmental Immunotherapy and Tumor Immunobiology
8:00am	11:00am	2560 (204)	Hall A	IOLite: Multipart, phase 1b, dose-finding study of the PD-1 inhibitor dostarlimab in combination with the PARP inhibitor niraparib 3 bevacizumab (bev), or with platinum-based chemotherapy 3 bev for advanced cancer	NY Gabrail	EP Hamilton, MR Patel	Poster	Developmental Immunotherapy and Tumor Immunobiology
8:00am	11:00am	2562 (206)	Hall A	Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors	MR Patel	MR Patel, GS Falchook, JS Wang, SF Jones, DR Spigel, EP Hamilton	Poster	Developmental Immunotherapy and Tumor Immunobiology
8:00am	11:00am	2611 (255)	Hall A	A phase 1/2a study of GEN-009, a neoantigen vaccine based on autologous peptide immune responses	RB Cohen	ML Johnson	Poster	Developmental Immunotherapy and Tumor Immunobiology
8:00am	11:00am	TPS2646 (289a)	Hall A	A phase 1/1b multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with pembrolizumab in adult patients with advanced cancers	M Mobasher	A Tripathy	Poster	Developmental Immunotherapy and Tumor Immunobiology

SARAH CANNON | ASCO® 2019

ABSTRACT PRESENTATION CALENDAR

SATURDAY, JUNE 1st

8:00 am - 1:00 pm (Continued)

Posters

Time Begin	Time End	ASCO ID (Poster Board #)	Location	Presentation Title	Presenter	Sarah Cannon Co-Authors	ASCO Selection Status	Session Category
8:00am	11:00am	TPS2655 (293b)	Hall A	A phase III trial-in-progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma	R Xu	H Arkenau	Poster	Developmental Immunotherapy and Tumor Immunology
8:00am	11:00am	TPS2657 (294b)	Hall A	A phase I study evaluating COM701 in patients with advanced solid tumors	DW Rasco	EP Hamilton	Poster	Developmental Immunotherapy and Tumor Immunobiology
8:00am	11:00am	TPS2660 (296a)	Hall A	JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti-PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect	DM Hyman	TM Bauer, SV Ulahannan	Poster	Developmental Immunotherapy and Tumor Immunobiology
8:00am	11:00am	TPS2661 (296b)	Hall A	A phase 1, first-in-human, open-label, dose escalation and cohort expansion study of MGD019, a bispecific DART® protein binding PD-1 and CTLA-4 in patients with unresectable or metastatic neoplasms	JJ Luke	JC Bendell	Poster	Developmental Immunotherapy and Tumor Immunobiology
8:00am	11:00am	TPS2665 (299b)	Hall A	Phase 1/1b Multicenter Trial of TPST-1120, a Peroxisome Proliferator-Activated Receptor Alpha (PPARα) Antagonist as a Single Agent (SA) or in Combination in Patients with Advanced Solid Tumors	G Laport	S Chokshi, JC Bendell	Poster	Developmental Immunotherapy and Tumor Immunobiology
8:00am	11:00am	11063 (386)	Hall A	Survival and signals of response in advanced sarcoma patients enrolled on phase 1 trials in the era of precision oncology and novel immunotherapies	S Sen	S Sen, GS Falchook	Poster	Sarcoma

Sessions

Time Begin	Time End	ASCO ID (Poster Board #)	Location	Presentation Title	Presenter	Sarah Cannon Co-Authors	ASCO Selection Status	Session Category
8:00am	9:30am		Hall D1	Fine-Tuning Checkpoint Inhibition: Biomarkers of Response and Resistance	ML Johnson (Chair)		Oral	Clinical Science Symposium

SARAH CANNON | ASCO® 2019

ABSTRACT PRESENTATION CALENDAR

SATURDAY, JUNE 1st

1:15 pm - 4:15 pm

Posters

Time Begin	Time End	ASCO ID (Poster Board #)	Location	Presentation Title	Presenter	Sarah Cannon Co-Authors	ASCO Selection Status	Session Category
1:15pm	4:15pm	10518 (97)	Hall A	Support structures for female physicians: Motivations and barriers to gender-specific conferences and symposia	S Jain	SL Graff	Poster	Education Research and Professional Development
1:15pm	4:15pm	5025 (137)	Hall A	Predictors of falls and fractures in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide plus ongoing androgen deprivation therapy	YG Pollack	S Chowdhury	Poster	Genitourinary (Prostate) cancer
1:15pm	4:15pm	5031 (143)	Hall A	Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in TRITON 2	W Abida	IJ Percent, S Chowdhury	Poster	Genitourinary (Prostate) cancer
1:15pm	4:15pm	TPS5086 (198a)	Hall A	Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and a circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or BRCA defects: A trial in progress	S Chowdhury	S Chowdhury	Poster	Genitourinary (Prostate) Cancer
1:15pm	4:15pm	6619 (310)	Hall A	Qualifying sites for oncology clinical trials	D Kurbegov	D Kurbegov	Poster	Health Services Research, Clinical Informatics, and Quality of Care
1:15pm	4:15pm	6635 (326)	Hall A	The effect of guideline-concordant novel therapy use on meeting cost targets in OCM: Results from a large community oncology network	SM Schleicher	SM Schleicher	Poster	Health Services Research, Clinical Informatics, and Quality of Care
1:15pm	4:15pm	5537 (360)	Hall A	A randomized, double-blind, placebo-controlled phase Ib/II study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine (G) and carboplatin (C) versus GC for women with recurrent platinum-sensitive ovarian cancer	I Vergote	KN Moore	Poster	Gynecologic Cancer

SARAH CANNON | ASCO® 2019

ABSTRACT PRESENTATION CALENDAR

SATURDAY, JUNE 1st

1:15 pm - 4:30 pm

Sessions

Time Begin	Time End	ASCO ID (Poster Board #)	Location	Presentation Title	Presenter	Sarah Cannon Co-Authors	ASCO Selection Status	Session Category
1:15pm	2:30pm		E350	Biden Cancer Initiative Colloquium: Clinical Trial Enrollment--Breaking the 5% Barrier Once and For All	M Correll (Panelist)		Education Session	Education Session
1:15pm	2:30pm		E253d	Impact of Right-to-Try Legislation	TM Bauer		Education Session (Ticketed)	Clinical Controversies: The Impact of Right-to-Try Legislation and Investigational Drugs for Patients Who Are Not Candidates for Clinical Trials
1:15pm	2:45pm	2513 (157)	Hall D1	CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: preliminary results of PROCLAIM-CX-072	A Naing	H Arkenau	Poster Discussion	Developmental immunotherapy and Tumor Immunobiology (8:00 - 11:00am)
1:15pm	2:45pm	2523 (167)	Hall D1	A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors	HA Burris	HA Burris, MR Patel	Poster Discussion	Developmental Immunotherapy and Tumor Immunobiology (8:00 - 11:00am)
3:00pm	4:30pm	3010 (2)	E450	Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b	AW Tolcher	SV Ulahannan, HA Burris, KN Moore, EP Hamilton	Poster Discussion	Developmental Therapeutics and Tumor Biology (Nonimmuno) (8:00 - 11:30)
3:00pm	4:30pm	11018 (341)	S404	Precision oncology in sarcoma drug development: Impact of genomic matching on response, clinical benefit, and survival in sarcoma patients on phase 1 trials	S Sen	S Sen, GS Falchook	Poster Discussion	Sarcoma (8:00 - 11:00am)
3:03pm	3:15pm	8505	Hall D2	Effect of trilaciclib, a CDK 4/6 inhibitor, on myelosuppression in patients with previously treated extensive-stage small cell lung cancer receiving topotecan	LL Hart	LL Hart, MA Hussein, R Aljumaili, DR Spigel	Oral Abstract Session	Lung Cancer—Non-Small Cell Local-Regional/ Small Cell/Other Thoracic Cancers (1:15 - 4:15)
3:12pm	3:24pm	7001	E451	A randomized phase II trial of CX-01 with standard therapy in elderly patients with acute myeloid leukemia (AML)	T Kovacs	WB Donnellan, M Maris	Oral Abstract Session	Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allogeneic Transplant (3:00 - 6:00pm)

SARAH CANNON | ASCO® 2019

ABSTRACT PRESENTATION CALENDAR

SATURDAY, JUNE 1st

4:30 pm - 6:00 pm

Sessions

Time Begin	Time End	ASCO ID (Poster Board #)	Location	Presentation Title	Presenter	Sarah Cannon Co-Authors	ASCO Selection Status	Session Category
4:30pm	6:00pm	5009 (121)	Arie Crown Theater	Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone	C Sweeney	IJ Percent, J Cultrera, JC Bendell	Poster Discussion	Genitourinary (Prostate) Cancer (1:15 - 4:15pm)
4:30pm	6:00pm	5019 (131)	Arie Crown Theater	Targeted next generation sequencing (tNGS) of metastatic castrate-sensitive prostate cancer (M1 CSPC): a pilot molecular analysis in the STAMPEDE multi-center trial	C Gilson	S Chowdhury	Poster Discussion	Genitourinary (Prostate) Cancer (1:15 - 4:15pm)
4:30pm	6:00pm	5513 (336)	S406	Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study	KN Moore	KN Moore, EP Hamilton, D Spitz, SF Jones, DR Spigel	Poster Discussion	Gynecologic Cancer (1:15 - 4:15pm)
4:30pm	6:00pm	5520 (343)	S406	Mirvetuximab soravtansine, a folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study	DM O'Malley	KN Moore	Poster Discussion	Gynecologic Cancer (1:15 - 4:15pm)
5:00pm	5:12pm	7006	E451	End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL)	BD Shah	WB Donnellan	Oral Abstract Session	Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft (3:00 - 6:00pm)

SARAH CANNON | ASCO® 2019

ABSTRACT PRESENTATION CALENDAR

SUNDAY, JUNE 2nd

8:00 am - 11:00 am

Posters

Time Begin	Time End	ASCO ID (Poster Board #)	Location	Presentation Title	Presenter	Sarah Cannon Co-Authors	ASCO Selection Status	Session Category
8:00am	11:00am	1030 (111)	Hall A	High frequency of HER2-specific immunity observed in patients (pts) with HER2+ cancers treated with margetuximab (M), an Fc-enhanced anti-HER2 monoclonal antibody (mAb)	JL Nordstrom	TM Bauer, HA Burris	Poster	Breast Cancer—Metastatic
8:00am	11:00am	1042 (123)	Hall A	Next-generation sequencing (NGS) results among hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) patients treated with a CDK4 & 6 inhibitor: A retrospective observational study based on real-world data	EP Hamilton	EP Hamilton, D Schlauch, A Misch, S Picard, HA Burris, DR Spigel	Poster	Breast Cancer—Metastatic
8:00am	11:00am	1044 (125)	Hall A	Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study	S Diab	DA Yardley	Poster	Breast Cancer—Metastatic
8:00am	11:00am	1052 (133)	Hall A	Molecular characterization and monitoring of patient ctDNA in phase I study of H3B-6545 in ER+ MBC	V Rimkunas	EP Hamilton, JS Wang	Poster	Breast Cancer—Metastatic
8:00am	11:00am	1059 (140)	Hall A	Phase I dose escalation of H3B-6545, a first-in-class highly Selective ER δ Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast cancer (HR+ BC)	EP Hamilton	EP Hamilton, JS Wang	Poster	Breast Cancer—Metastatic
8:00am	11:00am	TPS1101 (181b)	Hall A	B-PRECISE-01 Study: A phase 1b trial of MEN1611, a PI3K inhibitor, combined with trastuzumab3 fulvestrant for the treatment of HER2-positive advanced or metastatic breast cancer	MJ Piccart-Gebhart	H Arkenau	Poster	Breast Cancer-Metastatic
8:00am	11:00am	8526 (282)	Hall A	Three-year overall survival update from the PACIFIC trial	JE Gray	DB Daniel, DR Spigel	Poster	Lung Cancer-Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
8:00am	11:00am	8562 (318)	Hall A	RESILIENT: Study of irinotecan liposome injection (nal-IRI) in patients with small cell lung cancer—Preliminary findings from part 1 dose-defining phase	LG Paz-Ares	DR Spigel	Poster	Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
8:00am	11:00am	9054 (377)	Hall A	First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC	D Planchard	DB Daniel	Poster	Lung Cancer—Non-Small Cell Metastatic
8:00am	11:00am	9093 (416)	Hall A	Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies	JR Brahmer	ML Johnson	Poster	Lung Cancer—Non-Small Cell Metastatic

SARAH CANNON | ASCO® 2019

ABSTRACT PRESENTATION CALENDAR

SUNDAY, JUNE 2nd

8:00 am - 11:00 am (Continued)

Posters

Time Begin	Time End	ASCO ID (Poster Board #)	Location	Presentation Title	Presenter	Sarah Cannon Co-Authors	ASCO Selection Status	Session Category
8:00am	11:00am	TPS1103 (182b)	Hall A	XENERA-1: A phase II trial of xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement	P Schmid	HA Burris	Poster	Breast Cancer—Metastatic
8:00am	11:00am	TPS1107 (184b)	Hall A	CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane	J O'Shaughnessy	DA Yardley	Poster	Breast Cancer—Metastatic
8:00am	11:00am	TPS8570 (325b)	Hall A	CANOPY-A: A phase III study of canakinumab as adjuvant therapy in patients with surgically resected non-small cell lung cancer (NSCLC)	EB Garon	DR Spigel	Poster	Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
8:00am	11:00am	TPS8577 (329a)	Hall A	Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC)	MD Smit	ML Johnson	Poster	Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
8:00am	11:00am	TPS9124 (442a)	Hall A	The CANOPY program: Canakinumab in patients (pts) with non-small cell lung cancer (NSCLC)	LG Paz-Ares	DR Spigel	Poster	Lung Cancer—Non-Small Cell Metastatic

SARAH CANNON | ASCO® 2019

ABSTRACT PRESENTATION CALENDAR

SUNDAY, JUNE 2nd

8:00 am - 11:00 am (Continued)

Sessions

Time Begin	Time End	ASCO ID (Poster Board #)	Location	Presentation Title	Presenter	Sarah Cannon Co-Authors	ASCO Selection Status	Session Category
7:30am	9:15am		Hall D1	Highlights of the Day Session I	ML Johnson (Chair)		Oral	Highlights of the Day Session I
7:58am	8:11am		S103	How to Prepare Fellows for the Transition to Private Practice	SL Graff		Education Session	Training Program Directors' Breakfast (Training Program Directors and Associate Training Program Directors Only)
8:00am	11:00am		S404	Health Services Research, Clinical Informatics, and Quality of Care II	FP Gardner (Chair)		Oral	Oral Abstract Session: Health Services Research, Clinical Informatics, and Quality of Care
8:48am	9:00am	5511	S406	A phase II randomized study of avelumab plus entinostat versus avelumab plus placebo in patients (pts) with advanced epithelial ovarian cancer (EOC)	KA Cadoo	EP Hamilton	Oral	Clinical Science Symposium: Are We Hitting the Bull's-eye With Targeted Therapy? (8:00 - 9:30AM)
9:45am	12:45pm		E451	It's Not All About CAR T: What's New in Immunotherapy? (Abstract Discussion)	JG Berdeja (chair)		Oral	Oral Abstract Session: Hematologic Malignancies—Plasma Cell Dyscrasia
10:24am	10:36am	2508	Hall D2	First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), 3 cemiplimab in patients (pts) with advanced malignancies	KP Papadopoulos	ML Johnson, SV Ulahannan	Oral	Developmental immunotherapy and Tumor Immunobiology (8:00 - 11:00am)
10:25am	10:45am		S100a	Potential Pitfalls of a Research Program in the Community	SL Graff		Education Session	Building a Sustainable Research Program in the Community Practice Setting: First Steps, Essential Priorities, and Pitfalls Every Investigator Should Know

SARAH CANNON | ASCO® 2019

ABSTRACT PRESENTATION CALENDAR

SUNDAY, JUNE 2nd

11:15 am - 6:00 pm

Sessions

Time Begin	Time End	ASCO ID (Poster Board #)	Location	Presentation Title	Presenter	Sarah Cannon Co-Authors	ASCO Selection Status	Session Category
11:15am	12:45pm	8516 (272)	S406	Ph1/2 study of Rova-T in combination with nivolumab (Nivo) 3 ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC	J Malhotra	ML Johnson	Poster Discussion	<i>Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers (8:00am - 11:00am)</i>
11:15am	12:45pm	1016 (97)	Hall D2	Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2D advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITY-1): Efficacy, safety, and biomarker results	A Bardia	DA Yardley, LL Hart	Poster Discussion	<i>Breast Cancer—Metastatic (8:00 - 11:00am)</i>
11:15am	12:45pm	1017 (98)	Hall D2	A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2- metastatic breast cancer (MBC)	CK Anders	DA Yardley	Poster Discussion	<i>Breast Cancer—Metastatic (8:00 - 11:00am)</i>
11:30am	1:00pm		S103	Presentation of the 2019 Partners in Progress Award	HA Burris		Award Presentation	<i>Overcoming Barriers to Clinical Trial Enrollment (Includes Presentation of Partners in Progress Award)</i>
2:15pm	2:30pm	LBA2	Hall B1	Overall survival results of a phase III randomized trial of standard of care therapy with or without enzalutamide for metastatic hormone sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial	C Sweeney	S Chowdhury	Oral	<i>Plenary Session (1:00 - 4:00PM)</i>
4:30pm	6:00pm	9019 (342)	Hall D1	Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC)	AT Shaw	TM Bauer	Poster Discussion	<i>Lung Cancer—Non-Small Cell Metastatic (8:00am - 11:00am)</i>

SARAH CANNON | ASCO® 2019

ABSTRACT PRESENTATION CALENDAR

MONDAY, JUNE 3rd

8:00 am - 1:00 pm

Posters

Time Begin	Time End	ASCO ID (Poster Board #)	Location	Presentation Title	Presenter	Sarah Cannon Co-Authors	ASCO Selection Status	Session Category
8:00am	11:00am	3580 (72)	Hall A	Retrospective analysis of overall survival (OS) by subsequent therapy in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) receiving irinotecan 3 cetuximab in the EPIC study	AF Sobrero	HA Burris	Poster	Gastrointestinal (Colorectal) Cancer
8:00am	11:00am	4038 (143)	Hall A	Trifluridine/tipiracil (FTD/TPI) in patients with metastatic gastroesophageal junction cancer (mGEJC): subgroup analysis from TAGS	W Mansoor	H Arkenau	Poster	Gastrointestinal (Noncolorectal) Cancer
8:00am	11:00am	4039 (144)	Hall A	Pooled safety analysis from Phase 3 studies of trifluridine/tipiracil (FTD/TPI) in patients with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC) and metastatic colorectal cancer (mCRC)	E Van Cutsem	H Arkenau	Poster	Gastrointestinal (Noncolorectal) Cancer
8:00am	11:00am	4043 (148)	Hall A	Analysis of symptoms and functional HRQoL scales in TAGS, a phase III trial of trifluridine/tipiracil (FTD/TPI) in metastatic gastric cancer	M Alsina	H Arkenau	Poster	Gastrointestinal (Noncolorectal) Cancer
8:00am	11:00am	4124 (229)	Hall A	A Phase 1b Dose-Escalation and Cohort-Expansion Study of Safety and Activity of the Transforming Growth Factor (TGF) β Receptor I Kinase Inhibitor Galunisertib Plus the Anti-PD-L1 Antibody Durvalumab in Metastatic Pancreatic Cancer	D Melisi	JC Bendell	Poster	Gastrointestinal (Noncolorectal) Cancer
8:00am	11:00am	7523 (227)	Hall A	Effect of dose modifications on response to duvelisib in patients with relapsed/refractory (R/R) CLL/SLL in the DUO trial	I Flinn	I Flinn	Poster	Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
8:00am	11:00am	TPS7566 (320a)	Hall A	ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)	I Flinn	I Flinn, M Maris	Poster	Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
8:00am	11:00am	TPS7568 (321a)	Hall A	Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL)	S Opat	R Marcus	Poster	Hematologic Malignancies-lymphoma and chronic lymphocytic leukemia
8:00am	11:00am	8025 (351)	Hall A	A health-related quality of life (HRQoL) analysis of pomalidomide + low-dose dexamethasone + daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment	DE Reece	JG Berdeja, J Matous, BM Anz, G Fonseca	Poster	Hematologic Malignancies-Plasma Cell Dyscrasia

SARAH CANNON | ASCO® 2019

ABSTRACT PRESENTATION CALENDAR

MONDAY, JUNE 3rd

8:00 am - 1:00 pm

Sessions

Time Begin	Time End	ASCO ID (Poster Board #)	Location	Presentation Title	Presenter	Sarah Cannon Co-Authors	ASCO Selection Status	Session Category
8:12am	8:24am	3001	S406	A Phase 1 Dose Escalation (DE) Study of ERK Inhibitor - LY3214996 - in Advanced (adv) Cancer (CA) Patients (pts)	S Pant	JC Bendell, MR Patel	Oral	<i>Developmental Therapeutics and Tumor Biology (Nonimmuno) (8:00 - 11:00)</i>
9:00am	9:12am	3003	S406	Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors	M Fakih	GS Falchook	Oral	<i>Developmental Therapeutics and Tumor Biology (Nonimmuno) (8:00 - 11:00)</i>
9:45am	9:57am	1000	Hall D1	SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx)	HS Rugo	G Lynn S Wright	Oral	<i>Breast Cancer—Metastatic (9:45am - 12:45pm)</i>
10:09am	10:21am	502	Hall D2	HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial	OM Filho	DA Yardley	Oral Abstract Session	<i>Breast Cancer—Local/Regional/Adjuvant (9:45 - 12:45)</i>
10:24am	10:36am	3008	S406	Phase 1/2 trial of FF-10502-01, a pyrimidine antimetabolite, in patients with advanced cholangiocarcinoma and solid tumors	F Janku	S Sen, L Bramwell, C Stone, GS Falchook	Oral	<i>Developmental Therapeutics and Tumor Biology (Nonimmuno) (8:00 - 11:00)</i>
11:30am	1:00pm	7512 (226)	E450	Results of the PI3Kδ inhibitor ME-401 alone or with rituximab in relapsed/refractory follicular lymphoma	AD Zelenetz	AS Asch	Poster Discussion	<i>Hematologic Malignancies-lymphoma and chronic lymphocytic leukemia</i>
11:30am	1:00pm	7514 (268)	E450	Efficacy and time to next treatment following lenalidomide/rituximab (R2) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT)	JG Gribben	I Flinn	Poster Discussion	<i>Hematologic Malignancies-lymphoma and chronic lymphocytic leukemia (8:00 - 11:00am)</i>
11:30am	1:00pm	7518 (7518)	E450	Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma	NL Bartlett	I Flinn	Poster Discussion	<i>Hematologic Malignancies-lymphoma and chronic lymphocytic leukemia (8:00 - 11:00am)</i>
11:45am	11:57am	7506	E451	Umbaralisib monotherapy demonstrated efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: a multicenter, open label, registration directed phase II study	NH Fowler	JA Reeves	Oral	<i>Hematologic Malignancies-lymphoma and chronic lymphocytic leukemia 9:45am - 12:45pm)</i>

SARAH CANNON | ASCO® 2019

ABSTRACT PRESENTATION CALENDAR

MONDAY, JUNE 3rd

1:15 pm - 6:30 pm (Continued)

Posters

Time Begin	Time End	ASCO ID (Poster Board #)	Location	Presentation Title	Presenter	Sarah Cannon Co-Authors	ASCO Selection Status	Session Category
1:15pm	4:15pm	1545 (39)	Hall A	Prognostic significance of blood-based cancer detection in plasma cell-free DNA (cfDNA): Evaluating risk of overdiagnosis	GR Oxnard	DR Spigel	Poster	Cancer Prevention, Hereditary Genetics, and Epidemiology
1:15pm	4:15pm	4522 (348)	Hall A	Interim analysis of ibrutinib plus paclitaxel for patients with advanced urothelial carcinoma previously treated with platinum-based chemotherapy	DE Castellano	H Arkenau	Poster	Genitourinary (Nonprostate) Cancer
1:15pm	4:15pm	4553 (379)	Hall A	Correlation of circulating tumor DNA, tissue-based genomic profiling and clinical efficacy in the biomarker directed Ph1b trial in metastatic bladder cancer (BISCAY)	D Carroll	S Chowdhury	Poster	Genitourinary (Nonprostate) Cancer
1:15pm	4:15pm	9530 (101)	Hall A	Relationship between clinical efficacy and Aes of IMCgp100, a novel bispecific TCR-anti-CD3, in patients with advanced melanoma	M Middleton	JR Infante	Poster	Melanoma/skin cancers

Sessions

Time Begin	Time End	ASCO ID (Poster Board #)	Location	Presentation Title	Presenter	Sarah Cannon Co-Authors	ASCO Selection Status	Session Category
1:15pm	2:45pm	8018 (344)	E450	Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenstrom macroglobulinemia: results from IINOVA	A Tedeschi	J Matous	Poster Discussion	Hematologic Malignancies-Plasma Cell Dyscrasia (8:00 - 11:00am)
2:03pm	2:15pm	10503	S100bc	Evaluating unconscious bias: Speaker introductions at an international oncology conference	N Duma	SL Graff	Oral	Education Research and Workplace Inequities (1:15 - 2:45)
3:20pm	3:40pm		E253b	Treatment of Rare but Critical Mutations in Non-Small Cell Lung Cancer [TICKETED SESSION]	DR Spigel	DR Spigel	Ticketed Session: Meet the Professors	Meet the Professors: Treatment of Rare but Critical Mutations in Non-Small Cell Lung Cancer
4:30pm	6:30pm	9523 (94)	E451	Pharmacodynamic effect of IMCgp100 (TCR-CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma	MR Middleton	JR Infante	Poster Discussion	Melanoma/skin cancers (1:15 - 4:15PM)
4:30pm	6:30pm	4517 (343)	Hall D2	Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: interim analysis of CheckMate 920	H Enamekhoo	IJ Percent, JC Bendell, LN Gordan	Poster Discussion	Genitourinary (Prostate) Cancer (1:15 - 4:15pm)
4:30pm	6:30pm	4510 (336)	Hall D2	Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results	N Dizman	HA Burris	Poster Discussion	Genitourinary (Nonprostate) Cancer (1:15 - 4:15pm)

SARAH CANNON | ASCO® 2019

ABSTRACT PRESENTATION CALENDAR

MONDAY, JUNE 3rd

1:15 pm - 6:30 pm (Continued)

Sessions

Time Begin	Time End	ASCO ID (Poster Board #)	Location	Presentation Title	Presenter	Sarah Cannon Co-Authors	ASCO Selection Status	Session Category
4:30pm	6:30pm	7009 (384)	E450	The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results	David Andrew Sallman	WB Donnellan, AS Asch, S Kambhampati	Poster Discussion	Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft Transplant (8:00 - 11:00am)

TUESDAY, JUNE 4th

9:45am - 12:45pm

Posters

Time Begin	Time End	ASCO ID (Poster Board #)	Location	Presentation Title	Presenter	Sarah Cannon Co-Authors	ASCO Selection Status	Session Category
9:45am	12:45pm		Hall D1	Breast Cancer Metastatic Oral Abstract Session	EP Hamilton (Chair)		Oral	Breast Cancer Oral Abstract Session

FOR PUBLICATION ONLY

ASCO ID	Presentation Title	First Author	Sarah Cannon Co-Authors	ASCO Selection Status
e16509	Safety and preliminary immunogenicity of JNJ-64041809, a live attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer (mCRPC)	CG Drake	TM Bauer	Publication only
e18064	Adoption and utilization of NGS-based molecular profiling in community-based oncology practices: Insights from Sarah Cannon	A McKenzie	A McKenzie, D Schlauch, Y Sharma, DR Spigel, HA Burris, SF Jones, HH Dilks	Publication only
e18065	Mutational analysis of > 14,000 solid tumor NGS tests from community oncology practices: The Sarah Cannon Molecular Landscape	A McKenzie	A McKenzie, D Schlauch, Y Sharma, S Picard, C Higgins, A Misch, Y Xiao, R Lachs, N Oconnor, M Correll, DR Spigel, HA Burris, SF Jones, HH Dilks	Publication only
e14145	A phase 2, open-label, randomized, non-comparative study of eFT508 (tomivosertib) alone or in combination with avelumab in subjects with relapsed/refractory microsatellite stable colorectal cancer (MSS CRC)	JM Hubbard	MR Patel, GS Falchook, JC Bendell	Publication only
e18093	Automating incidental findings in radiology reports using natural language processing and machine learning to identify and classify pulmonary nodules	C French		Publication only
e14705	Pharmacokinetics of Ciclopirox Prodrug, A Novel Agent for the Treatment of Bladder Cancer, in Animals and Humans	SJ Weir	MR Patel, SV Ulahannan, HA Burris, GS Falchook	Publication only
e18156	Barriers to clinical trial accrual: clinical trialists' perspectives	ES Kim	D Kurbegov	Publication only
e19505	Once weekly (70 mg/m ²) versus twice weekly (56 mg/m ²) dosing of carfilzomib for patients with relapsed and/or refractory multiple myeloma	P Moreau	JG Berdeja	Publication only
e13583	Molecular profiling using the 92-gene assay for tumor classification of brain metastases	AJ Brenner	FA Greco	Publication only
e14055	A relationship-based approach to improving the clinical trial experience	SM Helou	J Piggee	Publication only